Oguchi Disease

Oguchi disease is a very rare, inherited eye condition that primarily affects a person's ability to see in low light or darkness, a symptom known as night blindness. This difficulty with night vision is usually present from birth or early childhood. People with Oguchi disease typically have normal vision during the day, including normal sharpness of vision (visual acuity) and normal color vision. The condition is caused by genetic changes passed down from parents, who are usually carriers and do not have the disease themselves. A unique feature of Oguchi disease is something eye doctors call the "Mizuo-Nakamura phenomenon." When an eye doctor looks at the back of the eye (the retina) in a normally lit room, it has an unusual golden-yellow or silver-gray metallic shine. However, if the person stays in complete darkness for a few hours, this unusual color completely disappears, and the retina looks normal. The shine returns quickly once the lights are turned back on. This color change does not hurt and is a key sign that helps doctors diagnose the condition. For most people, Oguchi disease is "stationary," meaning the night blindness does not get worse over time, and daytime vision remains good throughout life. However, it is important to have regular check-ups with an eye doctor, as a small number of people with a specific genetic type of Oguchi disease may develop more progressive vision problems later in life. Currently, there is no cure for Oguchi disease, but understanding the condition can help patients and families manage the symptoms, such as using extra lighting in dark environments.

Condition category: Stationary Disorder

Prevalence: Extremely rare

Inheritance patterns: Autosomal Recessive

Age of onset: Infancy or early childhood

Clinical overview: Oguchi disease is a rare, autosomal recessive inherited retinal disorder characterized by congenital stationary night blindness (CSNB) and a unique morphological abnormality of the retina known as the Mizuo-Nakamura phenomenon. First described by Chuta Oguchi in 1907, the condition primarily affects the rod photoreceptors, which are responsible for vision in low-light conditions. Patients experience profound difficulty seeing in the dark from early childhood, while their daylight vision, visual acuity, and color vision typically remain normal. The hallmark clinical sign of Oguchi disease is the Mizuo-Nakamura phenomenon, a striking golden-yellow or silver-gray metallic discoloration of the fundus observed during standard ophthalmoscopy in a light-adapted state. Remarkably, this abnormal coloration completely disappears after prolonged dark adaptation (usually 2 to 3 hours), revealing a normal-appearing retina, only to return shortly after re-exposure to light. This phenomenon is highly specific to Oguchi disease and serves as a key diagnostic indicator. Genetically, Oguchi disease is classified into two types based on the underlying molecular defect. Oguchi disease-1 (OMIM 258100) is caused by mutations in the SAG gene, which encodes the S-antigen (visual arrestin). Oguchi disease-2 (OMIM 613411) is caused by mutations in the GRK1 gene, which encodes rhodopsin kinase. Both proteins are critical for the deactivation phase of the phototransduction cascade in rod cells. The condition is also cataloged under Orphanet number ORPHA:75382. While generally considered a stationary disorder, recent evidence suggests that some patients, particularly those with SAG mutations, may develop progressive retinal degeneration later in life.

Patient and family guide: Oguchi disease is a very rare, inherited eye condition that primarily affects a person's ability to see in low light or darkness, a symptom known as night blindness. This difficulty with night vision is usually present from birth or early childhood. People with Oguchi disease typically have normal vision during the day, including normal sharpness of vision (visual acuity) and normal color vision. The condition is caused by genetic changes passed down from parents, who are usually carriers and do not have the disease themselves. A unique feature of Oguchi disease is something eye doctors call the "Mizuo-Nakamura phenomenon." When an eye doctor looks at the back of the eye (the retina) in a normally lit room, it has an unusual golden-yellow or silver-gray metallic shine. However, if the person stays in complete darkness for a few hours, this unusual color completely disappears, and the retina looks normal. The shine returns quickly once the lights are turned back on. This color change does not hurt and is a key sign that helps doctors diagnose the condition. For most people, Oguchi disease is "stationary," meaning the night blindness does not get worse over time, and daytime vision remains good throughout life. However, it is important to have regular check-ups with an eye doctor, as a small number of people with a specific genetic type of Oguchi disease may develop more progressive vision problems later in life. Currently, there is no cure for Oguchi disease, but understanding the condition can help patients and families manage the symptoms, such as using extra lighting in dark environments.

Symptoms and clinical features: The hallmark symptom of Oguchi disease is congenital stationary night blindness (CSNB). Patients experience profound difficulty seeing in low-light environments or darkness, a symptom that is typically present from birth or early infancy. Parents often notice this when a child struggles to navigate in dimly lit rooms or outside at night. Despite this severe impairment in scotopic (night) vision, photopic (daylight) vision is generally unaffected. In the early stages and throughout most of their lives, patients typically maintain normal best-corrected visual acuity, normal visual fields, and normal color vision. A unique and defining clinical sign of Oguchi disease, observable by an ophthalmologist, is the Mizuo-Nakamura phenomenon. In a light-adapted state, the fundus (the back of the eye) exhibits a diffuse, striking golden-yellow or silver-gray metallic sheen. This discoloration is most prominent in the posterior pole and mid-periphery of the retina. Remarkably, after a period of prolonged dark adaptation—usually lasting 2 to 3 hours or more—this abnormal coloration completely vanishes, and the fundus appears entirely normal. Upon re-exposure to light, the metallic sheen gradually returns over 10 to 20 minutes. This phenomenon is present from an early age and remains a consistent feature of the disease. While classically described as a stationary condition, the clinical presentation can evolve in a subset of patients, particularly those with mutations in the SAG gene. In these individuals, the disease may progress to a phenotype resembling retinitis pigmentosa (RP) in later stages (intermediate to advanced). This progression is characterized by the gradual loss of the characteristic golden fundus sheen, the development of bone spicule-like pigmentation in the retina, progressive constriction of the visual fields, and eventually, a decline in central visual acuity. The onset of these progressive symptoms is highly variable, ranging from early adulthood to late in life, and represents a significant deviation from the typical stationary course of the disease.

Molecular pathology: The molecular pathology of Oguchi disease centers on the disruption of the visual phototransduction cascade, specifically the recovery phase in rod photoreceptors. Normal vision relies on the rapid activation and subsequent deactivation of rhodopsin, the light-sensitive receptor protein in rods. When light strikes rhodopsin, it activates a G-protein (transducin), initiating a cascade that leads to the closure of cation channels, hyperpolarization of the rod cell, and the transmission of a visual signal. For the rod to respond to subsequent light stimuli, activated rhodopsin must be quickly deactivated. This deactivation process involves two critical proteins: rhodopsin kinase (encoded by the GRK1 gene) and visual arrestin (encoded by the SAG gene). First, rhodopsin kinase phosphorylates the activated rhodopsin. This phosphorylation allows visual arrestin to bind to rhodopsin, physically blocking its interaction with transducin and effectively shutting off the signaling cascade. In Oguchi disease, mutations in either SAG (Oguchi type 1) or GRK1 (Oguchi type 2) result in the absence or dysfunction of these essential proteins. Without functional arrestin or rhodopsin kinase, activated rhodopsin remains active for an abnormally long period. This prolonged activation leads to sustained low levels of cyclic GMP (cGMP) and continuous closure of the outer segment cation channels. Consequently, the rod photoreceptors remain in a hyperpolarized, "light-adapted" state even in dim light or darkness. This inability to reset the phototransduction cascade explains the profound delay in dark adaptation and the characteristic night blindness experienced by patients. The exact mechanism underlying the Mizuo-Nakamura phenomenon (the light-dependent fundus discoloration) is not fully understood but is believed to be related to an abnormal accumulation of potassium or other ions in the extracellular space due to the prolonged rod hyperpolarization, or possibly structural changes in the photoreceptor outer segments.

Genetics: Oguchi disease is inherited in an autosomal recessive manner, meaning an affected individual must inherit two copies of a pathogenic variant, one from each parent. The parents are typically asymptomatic carriers. The disease is genetically heterogeneous and is classified into two types based on the causative gene: Oguchi disease-1 (CSNBO1) and Oguchi disease-2 (CSNBO2). Oguchi disease-1 is caused by mutations in the SAG gene (S-antigen visual arrestin), located on chromosome 2q37.1. The most common mutation, particularly in the Japanese population, is a homozygous 1-base pair deletion (c.1147delA), which leads to a premature stop codon and a truncated, non-functional arrestin protein. Other nonsense and frameshift mutations in SAG have also been identified. Interestingly, there is significant phenotypic variability associated with SAG mutations; while they typically cause stationary Oguchi disease, some individuals with the exact same mutations (even within the same family) may develop retinitis pigmentosa (RP47), a progressive retinal degeneration. The factors determining this genotype-phenotype divergence remain unclear. Oguchi disease-2 is caused by mutations in the GRK1 gene (G protein-coupled receptor kinase 1, also known as rhodopsin kinase), located on chromosome 13q34. Mutations in GRK1, including missense, nonsense, and frameshift variants, lead to a deficiency or complete loss of rhodopsin kinase activity. Unlike SAG mutations, GRK1 mutations have not been definitively linked to progressive retinitis pigmentosa, and patients with Oguchi disease-2 generally maintain a strictly stationary phenotype throughout their lives.

Diagnostic evaluation: The diagnosis of Oguchi disease is primarily clinical, relying on the hallmark presentation of congenital stationary night blindness coupled with the Mizuo-Nakamura phenomenon observed during fundoscopy. In a light-adapted state, the fundus exhibits a diffuse golden-yellow or silver-gray metallic sheen, particularly in the posterior pole and mid-periphery. Following prolonged dark adaptation (typically 2 to 3 hours or more), this abnormal discoloration completely disappears, revealing a normal-appearing fundus. No evidence of bone spicules, significant macular changes, or chorioretinal atrophy is typically observed, distinguishing it from progressive retinal degenerations. Optical coherence tomography (OCT) in Oguchi disease generally shows a preserved retinal structure, including an intact ellipsoid zone and normal macular thickness, which aligns with the stationary nature of the disease and preserved visual acuity. However, in some older patients or those with specific genetic variants, mild structural disruptions may be noted. Fundus autofluorescence (FAF) imaging usually does not show the widespread abnormalities characteristic of retinitis pigmentosa, though subtle changes might be present. Electrophysiological testing is crucial for confirming the diagnosis. The full-field electroretinogram (ERG) under standard dark-adapted conditions typically shows an absent or severely reduced rod response (b-wave). The bright-flash mixed rod-cone ERG often demonstrates a "negative" configuration, characterized by a preserved a-wave but a markedly reduced b-wave, indicating a post-phototransduction defect. Importantly, cone responses, including photopic single-flash and 30-Hz flicker ERGs, are usually within normal limits. Following extended dark adaptation (several hours), rod ERG responses may partially or fully recover in some patients, particularly those with SAG mutations. Genetic testing is the definitive method for confirming the diagnosis and determining the specific subtype (Oguchi disease-1 or -2). Targeted sequencing or gene panels including the SAG and GRK1 genes are employed to identify biallelic pathogenic variants. Differential diagnosis includes other forms of congenital stationary night blindness, fundus albipunctatus (which presents with white dots rather than a diffuse sheen), Stargardt disease, juvenile retinoschisis, and early-stage retinitis pigmentosa. The presence of the Mizuo-Nakamura phenomenon is the key distinguishing feature for Oguchi disease.

Differential diagnosis: Differential diagnosis of Oguchi disease includes: (1) Fundus albipunctatus — white dots rather than golden sheen; RDH5 or RPE65 mutations. (2) Congenital stationary night blindness (other forms) — no Mizuo-Nakamura phenomenon. (3) Retinitis pigmentosa (early) — progressive, eventually abnormal fundus. (4) Vitamin A deficiency — reversible, systemic signs, low serum retinol.

Natural history: Oguchi disease is classically described as a congenital and stationary condition. Symptoms of night blindness are typically present from birth or early infancy and are often noticed by parents when the child begins to navigate in low-light environments. The hallmark feature, the Mizuo-Nakamura phenomenon, is also present from an early age. For the majority of patients, the disease course is stable, with visual acuity, visual fields, and color vision remaining normal or near-normal throughout life. The profound delay in dark adaptation persists without significant worsening. However, long-term follow-up studies have revealed that the "stationary" nature of Oguchi disease may not be absolute for all patients, particularly those with SAG gene mutations. A subset of patients initially diagnosed with Oguchi disease-1 has been observed to develop progressive retinal degeneration later in life, clinically indistinguishable from retinitis pigmentosa (RP). This progression can involve the loss of the characteristic golden fundus sheen, the appearance of bone spicule pigmentation, progressive visual field constriction, and a decline in central visual acuity. The age at which this transition to a progressive phenotype occurs is highly variable, ranging from early adulthood to late in life (e.g., the 7th decade). The factors that trigger this progression in some individuals with SAG mutations, while others with the same mutations remain stable, are currently unknown. Patients with GRK1 mutations (Oguchi disease-2) appear to have a more strictly stationary course, with no documented cases of progression to retinitis pigmentosa to date.

Management and treatment research: ### Current management and monitoring There is no cure or condition-specific medical treatment for Oguchi disease. Management focuses on reducing the practical effects of congenital stationary night blindness (nyctalopia) and monitoring eye health over time. Helpful strategies may include: - Using consistent, adequate lighting at home, school, and work - Carrying a flashlight or using a phone light in dim environments - Allowing extra time for the eyes to adapt when entering dark places - Avoiding driving at night or in poorly lit conditions when night vision is not adequate for safe driving - Discussing school, workplace, or mobility accommodations when needed Regular comprehensive eye examinations can help confirm that retinal function remains stable and identify findings that may suggest another eye condition. Testing may include visual acuity, dilated retinal examination, visual-field testing, dark-adaptation testing, and electroretinography (ERG). ERG measures the retina’s electrical responses to light. Genetic testing can help confirm the diagnosis. Oguchi disease is most often associated with disease-causing variants in **SAG** or **GRK1** and is generally inherited in an autosomal recessive pattern. Genetic counseling can help individuals and families understand inheritance, carrier testing, and reproductive options. ### Approved therapies No therapies are approved specifically for Oguchi disease. There is no established evidence that vitamin supplements, medications, or a special diet can restore normal dark adaptation in Oguchi disease. Sunglasses may improve comfort in bright light and provide general eye protection, but they do not treat the underlying retinal condition. ### Investigational therapies #### Gene-based research The **SAG** and **GRK1** genes provide instructions for proteins involved in phototransduction, the process by which retinal photoreceptor cells respond to light and recover after light exposure. This biology makes gene-based approaches a possible area of future research. However, there are currently no Oguchi disease–specific investigational treatments or clinical trials in the available pipeline and trial listings. Several gene therapy or genetic-treatment studies listed for other eye conditions do not apply to Oguchi disease. For example: - **OCU400** is being studied for retinitis pigmentosa and Leber congenital amaurosis in a Phase 1/2 study that is active but not recruiting (**NCT05203939**). It is not an Oguchi disease trial. - **QR-1123** has been studied for autosomal dominant retinitis pigmentosa caused by the **RHO** P23H variant (**NCT04123626**). This is not a treatment for Oguchi disease. - A natural-history study of retinitis pigmentosa associated with **PDE6A**, **PDE6B**, or **RHO** is active but not recruiting (**NCT06323772**). It does not include Oguchi disease. ### Clinical trial participation No Oguchi disease–specific treatment trials are currently identified in the available listings. People with Oguchi disease may consider registries or natural-history research. These studies do not provide treatment, but they can help researchers understand inherited retinal diseases and may support future research recruitment. The Inherited Retinal Degenerative Disease Registry is recruiting (**NCT02435940**). Eligibility should be confirmed directly with the study team.

Outlook: The overall visual prognosis for patients with Oguchi disease is generally favorable, especially when compared to progressive inherited retinal degenerations. Because the condition is typically stationary, most patients maintain normal or near-normal central visual acuity, intact visual fields, and normal color vision throughout their lives. The primary functional limitation is congenital night blindness, which requires behavioral adaptations, such as avoiding driving at night or in poorly lit conditions and utilizing supplemental lighting. With these adjustments, patients can generally lead normal, independent lives, and the condition does not significantly impact overall life expectancy or general health. However, the prognosis must be guarded for patients with Oguchi disease-1 (caused by SAG mutations), as long-term follow-up has shown that a subset of these individuals may eventually develop progressive retinitis pigmentosa. This progression can lead to visual field constriction and a decline in central vision later in life. Therefore, regular ophthalmological monitoring is essential for all patients with Oguchi disease to detect any signs of retinal degeneration early. Genetic counseling is also highly recommended to provide patients and families with accurate information regarding inheritance risks and the potential for disease progression based on their specific genetic profile.

Epidemiology: Oguchi disease is an extremely rare condition, with an estimated prevalence of less than 1 in 1,000,000 worldwide. To date, approximately 50 to 100 cases have been documented in the medical literature. The disease exhibits a distinct geographic and ethnic distribution, being most frequently reported in the Japanese population, where the carrier frequency for certain founder mutations (such as the 1147delA mutation in the SAG gene) is notably higher. While predominantly found in Japan, isolated cases have been identified in other populations, including European, American, Pakistani, and Indian individuals. The condition affects both males and females equally, consistent with its autosomal recessive inheritance pattern. Consanguinity is often a factor in cases occurring outside of Japan, increasing the likelihood of inheriting two copies of the rare pathogenic variants.

Selected references: 1. Fuchs S, et al. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet. 1995. PMID: 7670478 2. Yamamoto S, et al. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat Genet. 1997. PMID: 9020843 3. Nishiguchi KM, et al. Phenotypic features of Oguchi disease and retinitis pigmentosa in patients with S-antigen mutations: a long-term follow-up study. Ophthalmology. 2019. PMID: 31257036 4. Dryja TP. Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: Luedde Memorial Lecture. Am J Ophthalmol. 2000. PMID: 11053269 5. Nakamura M, et al. Novel mutations in the arrestin gene and associated clinical features in Japanese patients with Oguchi's disease. Ophthalmology. 2004. PMID: 15234147 6. Hayashi T, et al. A novel homozygous GRK1 mutation (P391H) in 2 siblings with Oguchi disease with markedly reduced cone responses. Ophthalmology. 2007. PMID: 17070587